- April 16, 2018 Spero Therapeutics Highlights SPR741 Phase 1 and Preclinical Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases
- April 12, 2018 Spero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical Microbiology
- April 02, 2018 Spero Therapeutics Announces Fourth Quarter and Full Year 2017 Operating Results and Provides Pipeline Update
- March 22, 2018 Spero Therapeutics to Present at Upcoming Investor Conferences
- March 01, 2018 Spero Therapeutics to Present at March Investor Conferences
- February 01, 2018 Spero Announces Appointment of David P. Southwell to its Board of Directors
- January 04, 2018 Spero Therapeutics Appoints David Melnick, M.D., as Chief Medical Officer
- December 14, 2017 Spero Therapeutics Announces 3Q17 Operating Results and Pipeline Update
- November 13, 2017 Spero Therapeutics Announces Underwriters’ Option Exercise
- November 06, 2017 Spero Therapeutics Announces Closing of Initial Public Offering
Displaying 1 - 10 of 50 results